The Oncology Clinical Trials Program enables patients to access a wide spectrum of newly advanced treatments including immunotherapeutic drugs and targeted therapies for a range of solid and haematological malignancies.

Established in 2003 and led by Associate Professor Gary Richardson OAM, the Department aims to provide compassionate, state-of-the-art care for cancer patients and continued advancements in the prevention, diagnosis, treatment and cure of cancer via a combination of research, education and clinical practice.

How can you participate in a clinical trial at Cabrini

The Szalmuk Family Department of Medical Oncology currently has more than 100 active clinical trials covering many different cancer streams. If you are interested in participating in a trial, please speak to your treating oncologist first. Your oncologist will provide you with general information on clinical trials and also discuss programs that may be relevant to you.

All patients with private health insurance can participate, and in some trials public patients are also eligible.

You can also contact our trial department directly on (03) 9508 3421 or by emailing to lihoonlai@cabrini.com.au with your enquiry. Support groups or consumer health organisations with an interest in a particular disease or condition may also have information on relevant trials, or be able to provide contact information for other patients who have been involved in trials.

 

Phase I

Protocol Number - ALE17001/FN-1501-UP1

A Phase 1, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics (PK) And Anti-Tumor Activity Of FN-1501 Monotherapy In Patients With Advanced Solid Tumors

Download more information >

Protocol Number - HLX20-001

A Phase 1 Study Of HLX20, A Human Monoclonal Antibody Targeting PD-L1Protein In Patients With Advanced Solid Tumors (HLX20)

Download more information >

Protocol Number - FPT155-001

Phase 1A/1B Study Of FPT155 In Patients With Advanced Solid Tumours

Download more information >

Protocol Number - CV202-103

A Phase 1b/2 Study Of BMS 813160 In Combination With Chemotherapy Or Nivolumab In Patients With Advanced Solid Tumors.

Download more information >

Protocol Number - AB928CSP0002

A Phase 1/1b Study To Evaluate The Safety And Tolerability Of Immunotherapy Combinations In Participants With Breast Or Gynecologic Malignancies

Download more information >

Protocol Number - BO40933

A Phase 1b, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Ipatasertib In Combination With Rucaparib In Patients With Advanced Breast, Ovarian, Or Prostate Cancer

Download more information >

Protocol Number - GO39932

A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating The Safety, Pharmacokinetics, And Activity Of GDC-9545 Alone Or In Combination With Palbociclib And/Or LHRH Agonist In Patients With Locally Advanced Or Metastatic Estrogen Receptor Positive Breast Cancer

Download more information >

Protocol Number - XNW7201-1-02

A Phase I, Open-Label, Multi-Center, Non-Randomized, Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetic Profile Of XNW7201 In Subjects With Advanced Solid Tumors

Download more information >

Protocol Number - CO41012

A Phase IB/III Study Of Ipatasertib Plus Palbociclib And Fulvestrant Versus Placebo Plus Palbociclib And Fulvestrant In Hormone Receptor Positive And Her2 Negative Locally Advanced Unresectable Or Metastatic Breast Cancer

Download more information >

Protocol Number - CS3005-101

A Phase I, Multi-Center, Open-Label, Dose Escalation Study Of CS3005 In Subjects With Advanced Solid Tumors

Download more information >

Protocol Number - CS1002-101

A Phase 1a/1b, Open-Label, Dose-Escalation And Dose-Expansion Study Of The Anti-CTLA-4 Monoclonal Antibody CS1002 As Monotherapy And In Combination With Anti-PD-1 Monoclonal Antibody CS1003 In Subjects with Advanced Solid Tumours

Download more information >

Protocol Number - CN1-101

A Phase I, Open Label, Multi-Centre, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumours or B-cell Lymphoma

Download more information >

Melanoma

Protocol Number - CA209-7CK

A prospective observational study in patients receiving adjuvant nivolumab therapy for resected
melanoma in Australia

Download more information >

Protocol Number - CA209-76K

A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma

Download more information >

Lung

Protocol Number - SGNLVA-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Download more information >

Protocol Number - PACIFIC-R

First Real-World Data On Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

Download more information >

Haematological / Blood cancers

Protocol Number - ACE-536-MDS-002

A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Epoetin Alfa For The Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (MDS) In ESA Naive Subjects Who Require Red Blood Cell Transfusions

Download more information >

Protocol Number - CN1-101

A Phase I, Open Label, Multi-Centre, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumours or B-cell Lymphoma

Download more information >

Colorectal

Protocol Number - WEHI-ctDNA11

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study

Download more information >

Protocol Number - AveRec Trial

Phase II Trial PD-L1/PD-1 Blockade Avelumab (MSB0010718C) With Chemoradiotherapy For Locally Advanced ResectableT3b-4/N1-2 Rectal Cancer

Download more information >

Genitourinary

Protocol Number - CA209914

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Download more information >

Protocol Number - BO40933

A Phase 1b, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Ipatasertib In Combination With Rucaparib In Patients With Advanced Breast, Ovarian, Or Prostate Cancer

Download more information >

Protocol Number - 64091742PCR3001

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study Of Niraparib In Combination With Abiraterone Acetate And Prednisone Versus Abiraterone Acetate And Prednisone For Treatment Of Subjects With Metastatic Prostate Cancer

Download more information >

Protocol Number - CA209-7DX

A Phase 3 Randomized, Double-Blind Study Of Nivolumab Or Placebo In Combination With Docetaxel, In Men With Metastatic Castration-resistant Prostate Cancer

Download more information >

Breast Cancer

Protocol Number - AB928CSP0002

A Phase 1/1b Study To Evaluate The Safety And Tolerability Of Immunotherapy Combinations In Participants With Breast Or Gynecologic Malignancies

Download more information >

Protocol Number - GO39932

A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating The Safety, Pharmacokinetics, And Activity Of GDC-9545 Alone Or In Combination With Palbociclib And/Or LHRH Agonist In Patients With Locally Advanced Or Metastatic Estrogen Receptor Positive Breast Cancer

Download more information >

Protocol Number - CO41012

A Phase IB/III Study Of Ipatasertib Plus Palbociclib And Fulvestrant Versus Placebo Plus Palbociclib And Fulvestrant In Hormone Receptor Positive And Her2 Negative Locally Advanced Unresectable Or Metastatic Breast Cancer

Download more information >

Gynaecological

Protocol Number - WEHI-ctDNA-10

Circulating Tumour DNA As A Marker Of Residual Disease And Response To Adjuvant Chemotherapy In Stage I-III Optimally Debulked Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer (EOC)

Download more information >

Protocol Number - AB928CSP0002

A Phase 1/1b Study To Evaluate The Safety And Tolerability Of Immunotherapy Combinations In Participants With Breast Or Gynecologic Malignancies

Download more information >

Gastrointestinal

Protocol Number - SGNLVA-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Download more information >

Pancreatic

Protocol Number - ct-DNA-09

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study (DYNAMIC-Pancreas)

Download more information >

There are no results to your search.

The keyword you entered is too short. Please use at least three characters.